bluebird bio (BLUE) Misses Q1 EPS by 15c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. DECK
2. RNG
3. WDC
4. BMY
5. BYD
6. WCN
7. SPOT
8. SPY
9. FIX
10. TSCO

Go back to bluebird bio (BLUE) Misses Q1 EPS by 15c

bluebird bio Reports First Quarter 2015 Financial Results and Business Updates

May 6, 2015 4:01 PM EDT

-- Achievement of initial enrollment targets in Starbeam and Northstar studies --

-- Presenting HGB-205 beta-thalassemia/sickle cell disease study update at EHA --

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and rare diseases and T cell-based immunotherapies, today reported business highlights and financial results for the first quarter ended March 31, 2015.

We are pleased with the strong start to 2015, especially the faster than expected enrollment for our key adrenoleukodystrophy and... More